Novartis exec pushed out over Zolgensma data scandal denies wrongdoing

pharmafile | August 21, 2019 | News story | Research and Development |  AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma 

Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement that he “categorically denies any wrongdoing.”

Speaking through a lawyer, Kaspar said he “stands proudly behind the safety and efficacy” of the $2.1 million gene therapy Zolgensma, and that he is “prepared to assert his rights and defend his conduct accordingly.”

The statement from law firm Heuston Hannigan, who previously represented Elon Musk, says: “Dr Brian Kaspar is a respected member of the scientific community with an impeccable record. He stands proudly behind the safety and efficacy of the drug that he and his team worked so hard to develop, and which remains an FDA-approved drug that is saving the lives of children who suffer from Spinal Muscular Atrophy.

Advertisement

“He has cooperated with Avexis’ internal investigation, and he categorically denies any wrongdoing. He is prepared to assert his rights and defend his conduct accordingly. Dr Kaspar continues to wish clinicians and the company continued success in the treatment of children with this deadly and devastating disease.”

Louis Goss

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine

The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

The Gateway to Local Adoption Series

Latest content